Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000410748 | SCV000486640 | likely pathogenic | Metachromatic leukodystrophy | 2016-07-08 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000410748 | SCV001581839 | pathogenic | Metachromatic leukodystrophy | 2020-03-08 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 6 of the ARSA gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. This variant is not present in population databases (ExAC no frequency). Disruption of this splice site has been observed in individuals affected with ARSA-related conditions (PMID: 26131420, 20890085). ClinVar contains an entry for this variant (Variation ID: 371139). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in ARSA are known to be pathogenic (PMID: 8962139, 10477432). For these reasons, this variant has been classified as Pathogenic. |
Natera, |
RCV000410748 | SCV002081645 | pathogenic | Metachromatic leukodystrophy | 2021-04-19 | no assertion criteria provided | clinical testing |